These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 24472409)

  • 21. MiR-378 as a biomarker for response to anti-angiogenic treatment in ovarian cancer.
    Chan JK; Kiet TK; Blansit K; Ramasubbaiah R; Hilton JF; Kapp DS; Matei D
    Gynecol Oncol; 2014 Jun; 133(3):568-74. PubMed ID: 24680769
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R.
    Zhang Y; Huang S; Guo Y; Li L
    Biomed Pharmacother; 2018 Oct; 106():1357-1363. PubMed ID: 30119207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Over-expression of miR-31 or loss of KCNMA1 leads to increased cisplatin resistance in ovarian cancer cells.
    Samuel P; Pink RC; Caley DP; Currie JM; Brooks SA; Carter DR
    Tumour Biol; 2016 Feb; 37(2):2565-73. PubMed ID: 26386726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1.
    Xu S; Fu GB; Tao Z; OuYang J; Kong F; Jiang BH; Wan X; Chen K
    Oncotarget; 2015 Sep; 6(28):26457-71. PubMed ID: 26238185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1.
    Wu DD; Li XS; Meng XN; Yan J; Zong ZH
    Tumour Biol; 2016 Aug; 37(8):10499-506. PubMed ID: 26850595
    [TBL] [Abstract][Full Text] [Related]  

  • 26. miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.
    Sun C; Li N; Yang Z; Zhou B; He Y; Weng D; Fang Y; Wu P; Chen P; Yang X; Ma D; Zhou J; Chen G
    J Natl Cancer Inst; 2013 Nov; 105(22):1750-8. PubMed ID: 24168967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MiR-216b increases cisplatin sensitivity in ovarian cancer cells by targeting PARP1.
    Liu Y; Niu Z; Lin X; Tian Y
    Cancer Gene Ther; 2017 May; 24(5):208-214. PubMed ID: 28281524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. miR-378a-3p sensitizes ovarian cancer cells to cisplatin through targeting MAPK1/GRB2.
    Xu ZH; Yao TZ; Liu W
    Biomed Pharmacother; 2018 Nov; 107():1410-1417. PubMed ID: 30257357
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Regulatory effects and associated mechanisms of miR-130a molecules on cisplatin resistance in ovarian cancer A2780 cell lines].
    Li NW; Wang HJ; Yang LY; Jia XB; Chen C; Wang X
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Nov; 44(6):865-70. PubMed ID: 24490491
    [TBL] [Abstract][Full Text] [Related]  

  • 30. miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.
    Zhu W; Xu H; Zhu D; Zhi H; Wang T; Wang J; Jiang B; Shu Y; Liu P
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):723-31. PubMed ID: 21993663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells.
    Asselin E; Mills GB; Tsang BK
    Cancer Res; 2001 Mar; 61(5):1862-8. PubMed ID: 11280739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Restoration of microRNA-708 sensitizes ovarian cancer cells to cisplatin via IGF2BP1/Akt pathway.
    Qin X; Sun L; Wang J
    Cell Biol Int; 2017 Oct; 41(10):1110-1118. PubMed ID: 28685895
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
    Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer.
    Ji T; Gong D; Han Z; Wei X; Yan Y; Ye F; Ding W; Wang J; Xia X; Li F; Hu W; Lu Y; Wang S; Zhou J; Ma D; Gao Q
    Cancer Lett; 2013 Dec; 341(2):231-9. PubMed ID: 23962558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
    Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA-155 promotes apoptosis in SKOV3, A2780, and primary cultured ovarian cancer cells.
    Chen W; Huang L; Hao C; Zeng W; Luo X; Li X; Zhou L; Jiang S; Chen Z; He Y
    Tumour Biol; 2016 Jul; 37(7):9289-99. PubMed ID: 26779627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B.
    Xiao F; Li Y; Wan Y; Xue M
    Cancer Chemother Pharmacol; 2018 May; 81(5):935-947. PubMed ID: 29594361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. L-Tetrahydropalmatine enhances the sensitivity of human ovarian cancer cells to cisplatin via microRNA-93/PTEN/Akt cascade.
    Gong J; Xing C; Wang LY; Xie SS; Xiong WD
    J BUON; 2019; 24(2):701-708. PubMed ID: 31128026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MiR-155 inhibits the sensitivity of lung cancer cells to cisplatin via negative regulation of Apaf-1 expression.
    Zang YS; Zhong YF; Fang Z; Li B; An J
    Cancer Gene Ther; 2012 Nov; 19(11):773-8. PubMed ID: 22996741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reversal of cisplatin resistance by microRNA-139-5p-independent RNF2 downregulation and MAPK inhibition in ovarian cancer.
    Chen Y; Cao XY; Li YN; Qiu YY; Li YN; Li W; Wang H
    Am J Physiol Cell Physiol; 2018 Aug; 315(2):C225-C235. PubMed ID: 29719173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.